REVIEW ARTICLE

Liquid Biopsy: The Potential to Revolutionize Cancer Diagnostics and Treatment

Ruechuta Molek, MNS[1], Phongthara Vichitvejpaisal, MD, PhD[2], Wisut Lamlertthon, MD[3]

[1] Inpatient Department, Chulabhorn Hospital, Bangkok, Thailand; [2] Department of Anesthesiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; [3] Princess Srisavangavadhana College of Medicine, Chulabhorn Royal Academy, Bangkok, Thailand

The present article delved into the potential of liquid biopsy to revolutionize cancer diagnostics and treatment by addressing the current challenges in the field. Liquid biopsy, a non-invasive procedure, involves the detection and analysis of biomarkers in bodily fluids, offering advantages over traditional tissue biopsies. It provides a promising solution to the need for real-time monitoring, personalized treatment approaches, early detection, and minimal residual disease assessment in cancer care. By exploring various applications, such as early detection, treatment monitoring, minimal residual disease assessment, genetic profiling, personalized medicine, and prognostic evaluation, liquid biopsy emerges as a valuable tool in advancing cancer diagnostics and treatment.

The present article also discussed current developments, future directions, and provided case studies and success stories showcasing the impact of liquid biopsy. Overall, liquid biopsy holds great promise in transforming cancer care by enabling early detection, personalized treatment decisions, and real-time monitoring of tumors.

Keywords: Early cancer detection; Liquid biopsy; Minimal residual disease assessment; Traditional tissue biopsy

Received 18 September 2023 | Revised 13 November 2023 | Accepted 15 November 2023

J Med Assoc Thai 2023;106(12):1167-71

Website: http://www.jmatonline.com

Liquid biopsy is a non-invasive medical procedure that involves the detection and analyses of biomarkers in a patient's bodily fluids, such as blood, urine, or cerebrospinal fluid. Unlike traditional tissue biopsies, which require invasive procedures, liquid biopsy offers a less burdensome approach to cancer diagnostics and monitoring. While conventional tissue biopsies can be invasive, uncomfortable, and pose certain risks to patients, liquid biopsy, on the other hand, provides a minimally invasive alternative that allows for easier sample collection and monitoring over time. This less invasive approach has the potential to improve patient compliance, reduce risks, and enable more frequent and convenient testing.

The present article's primary focus was to explore the potential of liquid biopsy in revolutionizing cancer diagnostics and treatment. It sets the stage for discussing the various applications and benefits of liquid biopsy, highlighting its ability to detect cancer at early stages, monitor treatment response, assess minimal residual disease (MRD), provide personalized medicine approaches, and serve as prognostic and predictive tools.

Correspondence to:

Vichitvejpaisal P.

Department of Anesthesiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.

Phone: +66-81-8384393

Email: phongthara@gmail.com

How to cite this article:

Molek R, Vichitvejpaisal P, Lamlertthon W. Liquid Biopsy: The Potential to Revolutionize Cancer Diagnostics and Treatment. J Med Assoc Thai 2023;106:1167-71.

DOI: 10.35755/jmedassocthai.2023.12.13918

Current challenges in cancer diagnostics and treatment

Traditional tissue biopsies have been the gold standard for diagnosing cancer for many years[(1)], however, they have certain limitations. Tissue biopsies often require invasive procedures, which can be uncomfortable for patients and carry risks such as bleeding, infection, and damage to surrounding tissues. Moreover, obtaining tissue samples may not always be feasible, especially for tumors located in delicate or inaccessible areas. Additionally, tissue biopsies provide a single snapshot of the tumor at a specific point in time and may not capture the heterogeneity or evolution of cancer cells[(2)].

Since cancer is a dynamic disease that can evolve over time and respond differently to various treatments, traditional diagnostic methods, such as imaging scans, can provide valuable information



Figure 1. Liquid biopsy is a diagnostic technique that includes the examination of circulating tumor DNA (ctDNA) found in the bloodstream. CtDNA contains tumor-specific genetic alterations, such as mutations, amplifications, or rearrangements. Various methods, such as next-generation sequencing (NGS), polymerase chain reaction (PCR), or digital droplet PCR, are employed to identify and analyze ctDNA in liquid biopsy samples. Additionally, exosomes, small vesicles released by cancer cells, can be isolated from bodily fluids and examined for their content of genetic material, proteins, and other molecules.

but lack the ability to offer real-time monitoring of tumor behavior and treatment response[3]. The lack of timely information may lead to delayed treatment modifications or ineffective therapies[4]. Additionally, cancer treatment approaches are increasingly shifting towards personalized medicine, where therapies are tailored to individual patients based on their unique genetic makeup. Traditional biopsies may not capture the full genomic profile of a tumor, hindering the implementation of personalized treatment strategies[5].

As a result, early detection of cancer is crucial for improving patient outcomes. Unfortunately, many cancers are diagnosed at advanced stages when treatment options are limited, and the prognosis is poor[6]. Traditional screening methods, such as mammograms or colonoscopies, have their own limitations and may not detect cancer at its earliest stages. Moreover, even after successful treatment, the presence of MRD, or tiny remnants of cancer cells that go undetected, can increase the risk of recurrence[7,8]. Accurate assessment of MRD is essential to guide post-treatment surveillance and prevent relapse[9].

In light of these challenges, there is a need for innovative and non-invasive approaches that can address the limitations of traditional tissue biopsies, provide real-time monitoring, facilitate personalized treatment decisions, and enhance early detection and MRD assessment. Liquid biopsy emerges as a promising solution that can overcome these obstacles and revolutionize cancer diagnostics and treatment. The subsequent sections of the article will delve into the potential of liquid biopsy and its applications in addressing these challenges.

Understanding liquid biopsy (Figure 1)[10]

Liquid biopsy involves the collection and analysis of biomarkers present in bodily fluids, primarily blood, urine, and cerebrospinal fluid. The procedure starts with the extraction of these fluids using minimally invasive techniques, such as a simple blood draw, or urine sample. The collected sample contains various components, including circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and exosomes. These components carry valuable genetic and molecular information related to the presence, characteristics, and progression of tumors[2].

Liquid biopsy enables the detection and analysis of CTCs, which are cancer cells that have detached from the primary tumor and entered the bloodstream. These cells can provide insights into tumor heterogeneity and dynamics, as well as potential metastatic spread. Advanced techniques, such as immunomagnetic separation or microfluidic-based approaches, allow

for the isolation and characterization of CTCs from the blood sample. The analysis of CTCs can provide information about tumor subtypes, genetic mutations, and treatment resistance[11].

Liquid biopsy also involves the analysis of ctDNA, which refers to fragments of tumor DNA that are shed into the bloodstream. ctDNA carries genetic alterations specific to the tumor, including mutations, amplifications, or rearrangements. Various methods, such as next-generation sequencing (NGS), polymerase chain reaction (PCR), or digital droplet PCR, are used to detect and analyze ctDNA in the liquid biopsy sample[12]. Additionally, exosomes, small vesicles released by cancer cells, can also be isolated from bodily fluids, and analyzed for their cargo of genetic material, proteins, and other molecules[13].

Accordingly, liquid biopsy offers advantages over traditional tissue biopsies in cancer diagnostics. Firstly, it is a non-invasive procedure that avoids the need for invasive surgeries or procedures, reducing patient discomfort and associated risks. Secondly, liquid biopsy provides a more comprehensive view of the tumor's genetic profile and heterogeneity by capturing the genetic information from multiple tumor sites. It enables real-time monitoring of tumor evolution and treatment response through serial sampling. Lastly, liquid biopsy offers convenience and accessibility as it allows for easier sample collection and can be repeated as needed throughout the course of the disease[5].

Applications of liquid biopsy

Liquid biopsy has emerged as a powerful tool with diverse applications in the field of cancer research and clinical practice. One of its key strengths lies in its potential for early cancer detection. By detecting CTCs or ctDNA in the bloodstream, liquid biopsy can identify cancer even at its early stages, prior to the manifestation of symptoms or detectability by traditional imaging techniques. This early detection capability allows for timely interventions and can significantly improve patient outcomes. Furthermore, liquid biopsy holds promise for population-wide cancer screening programs, offering a less invasive and potentially more accessible method for early detection of cancer[14].

Another crucial application of liquid biopsy is its role in monitoring tumor response to treatment and guiding therapy selection. By analyzing ctDNA or CTCs, liquid biopsy provides real-time insights into tumor dynamics, genetic alterations, and the emergence of treatment resistance. This enables clinicians to assess the effectiveness of ongoing therapies, identify emerging resistance mechanisms, and make timely adjustments to treatment plans. Liquid biopsy also assists in the selection of targeted therapies by identifying specific genetic mutations or alterations that can guide the use of precision medicine approaches[3].

After cancer treatment, the presence of MRD increases the risk of disease recurrence. Liquid biopsy offers a sensitive and accurate method for assessing MRD. By analyzing ctDNA or CTCs in follow-up samples, liquid biopsy can detect even low levels of residual disease, allowing for early intervention and closer surveillance[15]. The ability to detect MRD more precisely can improve post-treatment management and potentially prevent relapse.

Liquid biopsy enables comprehensive genetic profiling of tumors, providing valuable information about genetic mutations, alterations, and tumor heterogeneity. This genetic information plays a pivotal role in guiding personalized medicine approaches, where treatments are tailored to the specific genetic characteristics of the tumor. By analyzing ctDNA or CTCs, liquid biopsy can identify targetable genetic alterations, facilitating the matching of patients with appropriate targeted therapies. It optimizes treatment choices and improves patient outcomes by enabling precision medicine[12].

Moreover, liquid biopsy can identify prognostic and predictive biomarkers that inform patient prognosis and guide treatment decisions. By analyzing ctDNA or CTCs, liquid biopsy can detect specific genetic alterations or molecular signatures associated with disease aggressiveness, treatment response, or resistance. These biomarkers help clinicians stratify patients into different risk groups, predict treatment outcomes, and select the most effective therapeutic strategies. Liquid biopsy-based biomarkers have the potential to enhance prognostic evaluation and enable more personalized treatment decisions[16].

Significantly, liquid biopsy also plays a vital role in cancer research and clinical trials. It allows for the collection of serial samples from patients throughout the course of their disease, providing a valuable resource for studying tumor evolution, treatment response, and resistance mechanisms. Liquid biopsy-based biomarkers can serve as surrogate endpoints in clinical trials, facilitating more efficient evaluation of treatment efficacy. Additionally, liquid biopsy can aid in the identification of suitable patients for clinical

trials based on specific genetic profiles or biomarkers.

Current developments and future directions

Liquid biopsy techniques are constantly evolving, driven by advancements in technology. NGS platforms have significantly improved the sensitivity and accuracy of genetic analysis in liquid biopsies, allowing for the detection of rare genetic alterations and comprehensive genomic profiling. Moreover, advancements in microfluidics, digital PCR, and single-cell analysis have enhanced the isolation and characterization of CTCs and ctDNA. These technological advancements continue to refine the capabilities and utility of liquid biopsy in cancer diagnostics.

Furthermore, liquid biopsy is increasingly being incorporated into clinical practice, particularly in oncology. It is being used as a complementary tool to traditional tissue biopsies, providing additional insights into tumor dynamics, genetic alterations, and treatment response. As the technology becomes more accessible and standardized, liquid biopsy has the potential to become a routine part of cancer diagnostics and monitoring. In addition, it can facilitate real-time treatment decision-making, minimize invasive procedures, and enable more personalized and precise patient care[17].

Despite its promising applications, liquid biopsy still faces certain challenges and limitations. The detection and analysis of circulating tumor components in bodily fluids can be technically demanding, requiring highly sensitive and specific assays. Additionally, standardization of liquid biopsy protocols, including sample collection, processing, and analysis, is essential to ensure reproducibility and reliability across different laboratories and clinical settings. Furthermore, the interpretation and clinical significance of liquid biopsy results need further validation and standardization to guide treatment decisions accurately.

While liquid biopsy has primarily been explored in the field of oncology, its potential extends beyond cancer. Researchers are investigating its applications in other areas such as infectious diseases, prenatal testing, and transplantation medicine. Liquid biopsy has the potential to detect genetic material or biomarkers associated with infections, monitor organ transplant rejection, and assess fetal genetic abnormalities through the analysis of maternal blood samples. These emerging applications highlight the versatility of liquid biopsy as a diagnostic tool beyond cancer.

The future of liquid biopsy holds great promise. Continued advancements in technology, standardization of protocols, and validation of clinical utility will further enhance its role in cancer diagnostics and treatment. Moreover, as more data are accumulated and its value is established, liquid biopsy has the potential to transform patient care by enabling early detection, personalized treatment decisions, and real-time monitoring of cancer[18]. Additionally, its expansion into other medical fields may revolutionize diagnostics and monitoring in various disease contexts. In the next section of the article, the authors will explore case studies and success stories that highlight the impact of liquid biopsy in cancer diagnostics and treatment.

Conclusion

Liquid biopsy is a non-invasive procedure, involving the detection and analysis of biomarkers in bodily fluids, which offers significant advantages over traditional tissue biopsies. By analyzing CTCs, ctDNA, and exosomes, liquid biopsy provides valuable insights into tumor dynamics, genetic alterations, and treatment response.

The applications of liquid biopsy in cancer are diverse and promising. It enables early detection of cancer, facilitating timely interventions and improved patient outcomes. It plays a vital role in monitoring treatment response, allowing for real-time adjustments and personalized treatment approaches. It also aids in assessing MRD, reducing the risk of recurrence and enhancing post-treatment surveillance.

Moreover, liquid biopsy enables genetic profiling and personalized medicine, identifying targetable genetic alterations and guiding treatment decisions. Prognostic and predictive biomarkers derived from liquid biopsy offer valuable information for patient prognosis and treatment selection. Liquid biopsy also plays a significant role in cancer research and clinical trials, facilitating the understanding of tumor biology, treatment response, and resistance mechanisms.

While there are still challenges to address, including standardization, technical refinement, and clinical validation, the field of liquid biopsy is continuously advancing. Technological developments are enhancing the sensitivity and accuracy of liquid biopsy techniques. Integration of liquid biopsy into clinical practice is expanding, enabling its routine use in cancer diagnostics and monitoring. Additionally, the potential of liquid biopsy extends beyond oncology, with emerging applications in infectious

diseases, prenatal testing, and transplantation medicine. This versatility highlights the broader impact and future prospects of liquid biopsy as a diagnostic tool in various medical fields.

What is already known on this topic?

Traditional tissue biopsies have limitations such as invasiveness, potential risks, and inability to capture tumor heterogeneity and evolution.

What does this study add?

This article highlights the potential of liquid biopsy to revolutionize cancer diagnostics and treatment. It discusses the current challenges in cancer diagnostics and treatment, emphasizing the need for real-time monitoring, personalized treatment approaches, early detection, and minimal residual disease assessment.

The article explores the applications of liquid biopsy in various aspects of cancer care, including early detection, treatment monitoring, minimal residual disease assessment, genetic profiling, personalized medicine, and prognostic evaluation. It provides case studies and success stories that demonstrate the impact of liquid biopsy in improving patient outcomes and highlights the potential in specific cancer types.

The article discusses current developments, future directions, and the broader implications of liquid biopsy beyond oncology. It emphasizes the need for continued research, standardization, and validation to fully realize the potential of liquid biopsy and its integration into clinical practice.

Conflicts of interest

The authors declare no conflict of interest.

References

1. Wilkinson AN. Cancer diagnosis in primary care: Six steps to reducing the diagnostic interval. Can Fam Physician 2021;67:265-8.
2. Mohanty A, Mohanty SK, Rout S, Pani C. Liquid Biopsy, the hype vs. hope in molecular and clinical oncology. Semin Oncol 2021;48:259-67.
3. Oellerich M, Schütz E, Beck J, Kanzow P, Plowman PN, Weiss GJ, et al. Using circulating cell-free DNA to monitor personalized cancer therapy. Crit Rev Clin Lab Sci 2017;54:205-18.
4. Gouda MA, Huang HJ, Piha-Paul SA, Call SG, Karp DD, Fu S, et al. Longitudinal monitoring of circulating tumor DNA to predict treatment outcomes in advanced cancers. JCO Precis Oncol 2022;6:e2100512.
5. Nikanjam M, Kato S, Kurzrock R. Liquid biopsy: current technology and clinical applications. J Hematol Oncol 2022;15:131.
6. Santucci C, Carioli G, Bertuccio P, Malvezzi M, Pastorino U, Boffetta P, et al. Progress in cancer mortality, incidence, and survival: a global overview. Eur J Cancer Prev 2020;29:367-81.
7. Tie J, Wang Y, Tomasetti C, Li L, Springer S, Kinde I, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med 2016;8:346ra92.
8. Pemmaraju N, Kantarjian H, Jorgensen JL, Jabbour E, Jain N, Thomas D, et al. Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission. Am J Hematol 2017;92:279-85.
9. Demaree A, Hewitt A, Eckert B, Lee LW. CLO20-035: Real-world Minimal Residual Disease (MRD) assessment and trends using clonoSEQ in B-cell acute lymphoblastic leukemia and multiple myeloma. J Natl Compr Canc Netw 2020;18:CLO20-035.
10. Pessoa LS, Heringer M, Ferrer VP. ctDNA as a cancer biomarker: A broad overview. Crit Rev Oncol Hematol 2020;155:103109.
11. Cai LL, Ye HM, Zheng LM, Ruan RS, Tzeng CM. Circulating tumor cells (CTCs) as a liquid biopsy material and drug target. Curr Drug Targets 2014;15:965-72.
12. Ma M, Zhu H, Zhang C, Sun X, Gao X, Chen G. "Liquid biopsy"-ctDNA detection with great potential and challenges. Ann Transl Med 2015;3:235.
13. Yu D, Li Y, Wang M, Gu J, Xu W, Cai H, et al. Exosomes as a new frontier of cancer liquid biopsy. Mol Cancer 2022;21:56.
14. Connal S, Cameron JM, Sala A, Brennan PM, Palmer DS, Palmer JD, et al. Liquid biopsies: the future of cancer early detection. J Transl Med 2023;21:118.
15. Nguyen HT, Nguyen TV, Nguyen Hoang VA, Tran DH, Le Trinh NA, Le MT, et al. Tumor genomic profiling and personalized tracking of circulating tumor DNA in Vietnamese colorectal cancer patients. Front Oncol 2022;12:1069296.
16. Brock G, Castellanos-Rizaldos E, Hu L, Coticchia C, Skog J. Liquid biopsy for cancer screening, patient stratification and monitoring. Transl Cancer Res 2015;4:280-90.
17. Esposito A, Criscitiello C, Locatelli M, Milano M, Curigliano G. Liquid biopsies for solid tumors: Understanding tumor heterogeneity and real time monitoring of early resistance to targeted therapies. Pharmacol Ther 2016;157:120-4.
18. Connors D, Allen J, Alvarez JD, Boyle J, Cristofanilli M, Hiller C, et al. International liquid biopsy standardization alliance white paper. Crit Rev Oncol Hematol 2020;156:103112.